The trial, conducted at the Pediatric Cancer and Blood Disorders Center of Armenia by the Immune Oncology Research Institute, has enrolled 27 patients and completed over 100 chemotherapy cycles after a year of its launch.
Despite numerous challenges, the trial has been made possible by a dedicated and exceptional team. It seeks to identify more effective methods for preventing chemotherapy-induced nausea and vomiting.
The investigators of the trial, Julieta Hoveyan MD and Ruzanna Papyan MD, anticipate concluding the trial and publishing the initial data by June 2025.
About IMMONC
Immune Oncology Research Institute (IMMONC) is dedicated to advancing research aimed at preventing, treating, and ultimately curing cancer while making these innovations accessible to those who need them. If you're interested in joining our team, please feel free to contact us at [email protected] or at +374-41 310-048